Van der Born D, Pees A, Poot AJ et al (2017) Fluorine-18 labelled building blocks for PET tracer synthesis. In: Late-stage fluorination of bioactive molecules and biologically-relevant substrates. Įdem PE, Steen EJL, Kjær A, Herth MM (2019) Fluorine-18 radiolabeling strategies-Advantages and disadvantages of currently applied labeling methods. Herth MM, Petersen IN, Hansen HD et al (2016) Synthesis and evaluation of 18F-labeled 5-HT 2A receptor agonists as PET ligands.
Labeling multiple peaks in mestrenova series#
Įttrup A, Hansen M, Santini MA et al (2011) Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT 2A agonist PET tracers. Pike VW (2009) PET radiotracers: crossing the blood-brain barrier and surviving metabolism. In: Guiard B, Di Giovanni G (eds) 5-HT 2A receptors in the central nervous system. Herth MM, Knudsen GM (2018) PET Imaging of the 5-HT 2A receptor system: a tool to study the receptor’s in vivo brain function. Herth MM, Leth-Petersen S, Lehel S et al (2014) Accelerating preclinical PET-screening: reductive amination with methoxybenzaldehydes. Guo Q, Brady M, Gunn RN (2009) A biomathematical modeling approach to central nervous system radioligand discovery and development. Zhang L, Villalobos A, Beck EM et al (2013) Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. įrank RA, Långström B, Antoni G et al (2007) The imaging continuum: bench to biomarkers to diagnostics. Miller PW, Long NJ, Vilar R, Gee AD (2008) Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron emission tomography. Piel M, Vernaleken I, Rösch F (2014) Positron emission tomography in CNS drug discovery and drug monitoring.
In: Stromgaard K, Krogsgaard-Larsen P, Madsen U (eds) Textbook of drug design and discovery, 5th edn. Kristensen JL, Herth MM (2017) In vivo imaging in drug discovery.
0 kommentar(er)
